Association Between ABCB1 Gene Polymorphisms and Drug-Resistant Epilepsy: an Integrative Review
DOI:
https://doi.org/10.1590/s2175-97902026e25063Palavras-chave:
Drug-resistant epilepsy, Genetic polymorphism, PharmacogeneticsResumo
ABCB1 gene polymorphisms have been associated with drug-resistant epilepsy (DRE). This integrative review evaluates the impact of key ABCB1 single nucleotide polymorphisms (SNPs)— C3435T (rs1045642), G2677T/A (rs2032582), and C1236T (rs1128503)—on the pharmacokinetics and therapeutic response to antiseizure medications (ASMs), including carbamazepine (CBZ), lamotrigine (LTG), and topiramate (TPM). Evidence suggests that these polymorphisms significantly affect CBZ and LTG efficacy by altering drug pharmacokinetics and increasing systemic exposure. In contrast, no consistent association has been observed between these variants and TPM response. These findings support the integration of pharmacogenetic information into clinical decision-making to optimize ASM therapy and reduce the risk of drug resistance in epilepsy management.
Downloads
Referências
Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines. Front Pharmacol. 2021 Jan 25;11:595219. doi: 10.3389/fphar.2020.595219.
Ahmed Juvale II, Abdul Hamid AA, Abd Halim KB, Che Has AT. P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease. Heliyon. 2022 Jun 22;8(6):e09777. doi: 10.1016/j.heliyon.2022.e09777.
Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001 Apr;11(3):217-21. doi: 10.1097/00008571-200104000-00005.
Amin ML. P-glycoprotein Inhibition for Optimal Drug Delivery. Drug Target Insights. 2013 Aug 19;7:27-34. doi: 10.4137/DTI.S12519.
Balram C, Sharma A, Sivathasan C, Lee EJD. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol. 2003 Jul;56(1):78-83. doi: 10.1046/j.1365-2125.2003.01820.x.
Barker TH, Stone JC, Sears K, Klugar M, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evidence Synthesis. 2023;21(3):494-506.
Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Protocolo Clínico e Diretrizes Terapêuticas para Epilepsia. Brasília (DF): Ministério da Saúde, 2022.
Budikayanti A, Khosama H, Octaviana F, Hamid DH, et al. Multidrug Resistance-1 C3435T Polymorphism and Carbamazepine Plasma Level in Indonesian Temporal Lobe Epilepsy Patients. Curr Drug Saf. 2023;18(1):62-68.
Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos. 2014 Apr;42(4):623-31.
Chaves JCS, Dando SJ, White AR, Oikari LE. Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer's disease and strategies for treatment. Biochim Biophys Acta Mol Basis Dis. 2024 Feb;1870(2):166967. doi: 10.1016/j.bbadis.2023.166967.
Chen Y, Xu S, Wang Z, Zhao M, et al. A Population Pharmacokinetic-Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy. Ther Drug Monit. 2018 Dec;40(6):730-737.
Chen Z, Brodie MJ, Ding D, Kwan P. Editorial: Epidemiology of epilepsy and seizures. Front Epidemiol. 2023;3:1273163.
Chouchi M, Kaabachi W, Klaa H, Tizaoui K, Turki IB, Hila L. Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis. BMC Neurol. 2017 Feb 15;17(1):32. doi: 10.1186/s12883-017-0801-x.
Elmagid, D.S.A, Abdelsalam, M, Magdy, H, Tharwat, N. The association between MDR1 C3435T genetic polymorphism and the risk of multidrug-resistant epilepsy in Egyptian children. Egypt J Med Hum Genet 22, 31 (2021). https://doi.org/10.1186/s43042-021-00152-1.
Emich-Widera E, Likus W, Kazek B, Sieroń AL, Urbanek K. Polymorphism of ABCB1/MDR1 C3435T in children and adolescents with partial epilepsy is due to different criteria for drug resistance - preliminary results. Med Sci Monit. 2014 Sep 16;20:1654-61.
Estrela RC, Ribeiro FS, Carvalho RS, Gregório SP, Dias-Neto E, Struchiner CJ, et al. Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics. 2008 Mar;9(3):267-76. doi: 10.2217/14622416.9.3.267.
Fan YX, Zhang Z, Meng JR, Yin SJ, Wang P, Zhou T, et al. Association of ABCB1 polymorphisms with carbamazepine metabolism and resistance in epilepsy: A meta-analysis. Epilepsy Res. 2021 Nov;177:106785. doi: 10.1016/j.eplepsyres.2021.106785.
Fariba KA, Saadabadi A. Topiramate. 2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32119417.
Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon CS, Dykeman J et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology. 2017 Jan 17;88(3):296-303. doi: 10.1212/WNL.0000000000003509.
Gidal BE. P-glycoprotein Expression and Pharmacoresistant Epilepsy: Cause or Consequence? Epilepsy Curr. 2014 May;14(3):136-8. doi: 10.5698/1535-7597-14.3.136.
Haerian BS, Lim KS, Mohamed EH, Tan HJ, Tan CT, Raymond AA, et al. Lack of association of ABCB1 haplotypes on five loci with response to treatment in epilepsy. Seizure. 2011a Sep;20(7):546-53. doi: 10.1016/j.seizure.2011.04.003.
Haerian BS, Lim KS, Mohamed EH, Tan HJ, Tan CT, Raymond AA, et al. Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy. Seizure. 2011b Jun;20(5):387-94. doi: 10.1016/j.seizure.2011.01.008.
Hippman C, Nislow C. Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges. J Pers Med. 2019 Aug 7;9(3):40. doi: 10.3390/jpm9030040.
Hsin CH, Stoffel MS, Gazzaz M, Schaeffeler E, Schwab M, Fuhr U, et al. Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin. Sci Rep. 2020 Jul 27;10(1):12457. doi: 10.1038/s41598-020-69326-y.
Hung CC, Chang WL, Ho JL, Tai JJ, Hsieh TJ, Huang HC, et al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics. 2012 Jan;13(2):159-69. doi: 10.2217/pgs.11.141.
Jiang Z, Fu Y, Shen H. UGT1A4*3 polymorphism influences serum concentration and therapeutic effect of lamotrigine for epilepsy treatment: A meta-analysis. PLoS One. 2024 Jul 18;19(7):e0307377.
Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001 Dec;11(9):803-8. doi: 10.1097/00008571-200112000-00008.
Kim V, Wal TV, Nishi MY, Montenegro LR, Carrilho FJ, Hoshida Y, et al. Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters. Pharmacogenomics. 2020 Jun;21(9):575-586. doi: 10.2217/pgs-2020-0013.
Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, etal. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007 Jan 26;315(5811):525-8. doi: 10.1126/science.1135308.
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010 Jun;51(6):1069-77. doi: 10.1111/j.1528-1167.2009.02397.x.
Leckband SG, Kelsoe JR, Dunnenberger HM, George AL Jr, Tran E, Berger R, et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther. 2013 Sep;94(3):324-8. doi: 10.1038/clpt.2013.103.
Löscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2005 Jan;2(1):86-98. doi: 10.1602/neurorx.2.1.86.
Lovrić M, Božina N, Hajnšek S, Kuzman MR, Sporiš D, Lalić Z, et al. Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. Ther Drug Monit. 2012 Oct;34(5):518-25. doi: 10.1097/FTD.0b013e31826517c6.
Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav. 2011 May;21(1):27-30. doi: 10.1016/j.yebeh.2011.02.015.
Moola S, Munn Z, Tufanaru C, Aromataris E, Sears, K, Sfetc, R, et al. . Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI, 2020. Available from https://synthesismanual.jbi.global.
Moshé SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. Lancet. 2015;385(9971):884–98.
Naslavsky MS, Scliar MO, Yamamoto GL, Wang JYT, Zverinova S, Karp T, et al. Whole-genome sequencing of 1,171 elderly admixed individuals from São Paulo, Brazil. Nat Commun. 2022 Mar 4;13(1):1004. doi: 10.1038/s41467-022-28648-3.
O'Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol. 2012 Jan;165(2):289-312. doi: 10.1111/j.1476-5381.2011.01557.
Olafuyi O, Parekh N, Wright J, Koenig J. Inter-ethnic differences in pharmacokinetics-is there more that unites than divides? Pharmacol Res Perspect. 2021 Dec;9(6):e00890. doi: 10.1002/prp2.890.
Ortega-Vázquez A, Fricke-Galindo I, Dorado P, Jung-Cook H, Martínez-Juárez IE, Monroy-Jaramillo N, et al. Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy. Pharmacogenomics J. 2020 Dec;20(6):845-856. doi: 10.1038/s41397-020-0173-2.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
Panebianco M, Bresnahan R, Ramaratnam S, Marson AG. Lamotrigine add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2020 Mar 20;3(3):CD001909. doi: 10.1002/14651858.CD001909.pub3. Update in: Cochrane Database Syst Rev. 2023 Dec 11;12:CD001909. doi: 10.1002/14651858.CD001909.pub4.
Petrenaite V, Öhman I, Jantzen FPT, Ekström L. Effect of UGT1A4, UGT2B7, UGT2B15, UGT2B17 and ABC1B polymorphisms on lamotrigine metabolism in Danish patients. Epilepsy Res. 2022 May;182:106897. doi: 10.1016/j.eplepsyres.2022.106897.
Phillips EJ, Sukasem C, Whirl-Carrillo M, Müller DJ, Dunnenberger HM, Chantratita W, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clin Pharmacol Ther. 2018 Apr;103(4):574-581. doi: 10.1002/cpt.1004.
Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, et al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013 Jan;14(1):35-45. doi: 10.2217/pgs.12.180.
Rashid HU, Ullah S, Carr DF, Khattak MIK, Asad MI, Rehman MU, et al. The association of ABCB1 gene polymorphism with clinical response to carbamazepine monotherapy in patients with epilepsy. Mol Biol Rep. 2024 Jan 25;51(1):191. doi: 10.1007/s11033-023-09061-5.
Riva A, Roberti R, D'Onofrio G, Vari MS, Amadori E, De Giorgis V, et al. A real-life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy. Epilepsia Open. 2023 Sep;8(3):1142-1150. doi: 10.1002/epi4.12717.
Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Jiang-Zheng C, Koller D, et al. Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):474-485. doi: 10.1111/bcpt.13031. Epub 2018 Jun 13. PMID: 29723928.
Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol. 2003;16:165–70.
Santos M, Lima L, Carvalho S, Brandão A, Barroso F, Cruz A, et al. ABCB1 C1236T, G2677TA and C3435T Genetic Polymorphisms and Antidepressant Response Phenotypes: Results from a Portuguese Major Depressive Disorder Cohort. Int J Mol Sci. 2024 May 8;25(10):5112. doi: 10.3390/ijms25105112.
Santos PC, Soares RA, Santos DB, Nascimento RM, Coelho GL, Nicolau JC, et al. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet. 2011 Jan 19;12:13. doi: 10.1186/1471-2350-12-13.
Saruwatari J, Ishitsu T, Nakagawa K. Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy. Pharmaceuticals (Basel). 2010;3(8):2709-2732.
Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 2001 Aug 4;358(9279):383-4. doi: 10.1016/S0140-6736(01)05579-9.
Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology. 2003 Jan;124(1):26-33. doi: 10.1053/gast.2003.50010.
Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K, et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics. 2006 Jun;7(4):551-61. doi: 10.2217/14622416.7.4.551.
Shahid A, Hameed K, Zainab A, Zafar A, Abbas S. Advances in pharmacogenomics: optimizing antiepileptic drug therapy for drug-resistant epilepsy. Explor Neuroprot Ther. 2024;4:240–50.
Sterjev Z, Trencevska GK, Cvetkovska E, Petrov I, Kuzmanovski I, Ribarska JT, et al. The association of C3435T single-nucleotide polymorphism, Pgp-glycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy. Neuropsychiatr Dis Treat. 2012;8:191-6. doi: 10.2147/NDT.S28285.
Suarez-Kurtz G, Pena SD, Struchiner CJ, Hutz MH. Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin. Front Pharmacol. 2012 Nov 6;3:191. doi: 10.3389/fphar.2012.00191.
Suarez-Kurtz G. Pharmacogenetic Testing in Admixed Populations: Frequency of the Association for Molecular Pathology Pharmacogenomics Working Group Tier 1 Variant Alleles in Brazilians. Front Pharmacol. 2010 Oct 4;1:118. doi: 10.3389/fphar.2010.00118.
Subenthiran S, Abdullah NR, Muniandy PK, Joseph JP, Mok BT, Kee CC, et al. Linkage disequilibrium between polymorphisms of ABCB1 and ABCC2 to predict the treatment outcome of Malaysians with complex partial seizures on treatment with carbamazepine mono-therapy at the Kuala Lumpur Hospital. PLoS One. 2013a May 23;8(5):e64827.
Subenthiran S, Abdullah NR, Muniandy PK, Joseph JP, Cheong KC, Ismail Z, et al. G2677T polymorphism can predict treatment outcome of Malaysians with complex partial seizures being treated with Carbamazepine. Genet Mol Res. 2013b Nov 26;12(4):5937-44.
Sun F, Cao BQ, Wang B, Wu SQ, Jiang DH. Association between ABCB1 genetic polymorphism and the effect on epilepsy following phenytoin treatment. Exp Ther Med. 2016 Sep;12(3):1780-1784.
Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008 Jan 24;57(2):203-9. doi: 10.1016/j.neuron.2007.11.017.
Wang ML, Tao YY, Sun XY, Guo Y, Wang ZY, Cao YF, et al. Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy. Pharmacol Res. 2021 Jul;169:105610. doi: 10.1016/j.phrs.2021.105610.
Wang P, Yin T, Ma HY, Liu DQ, Sheng YH, Wang C, et al. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Epilepsy Res. 2015 Nov;117:52-7. doi: 10.1016/j.eplepsyres.2015.09.001.
Yeung S, Ferrie CD, Murdoch-Eaton DG, Livingston JH. Topiramate for drug-resistant epilepsies. Eur J Paediatr Neurol. 2000;4(1):31-3.
Zhao T, Li HJ, Feng J, Zhang HL, Ting-Ting W, Ma L, et al. Impact of ABCB1 Polymorphisms on Lacosamide Serum Concentrations in Uygur Pediatric Patients With Epilepsy in China. Ther Drug Monit. 2022 Jun 1;44(3):455-464. doi: 10.1097/FTD.0000000000000927.
Zhou Y, Wang X, Li H, Zhang J, Chen Z, Xie W, et al. Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients. Drug Metab Pharmacokinet. 2015 Aug;30(4):282-7. doi: 10.1016/j.dmpk.2015.05.002.
Zhu X, Yun W, Sun X, Qiu F, Zhao L, Guo Y. Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics. 2014;15(15):1867-79. doi: 10.2217/pgs.14.142.
Downloads
Publicado
Declaração de Disponibilidade de Dados
Use of data not disclosed.
Edição
Seção
Licença
Direitos autorais (c) 2026 Brazilian Journal of Pharmaceutical Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
